Opko Health Presents Clinical Data On Its Long-Acting Human Growth Hormone (hGH-CTP) In Two Oral Presentations At The 54th Annual Meeting Of The European Society For Pediatric Endocrinology (ESPE)

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE: OPK) presented clinical data from its completed 12-month hGH-CTP Phase 2 pediatric growth hormone deficiency clinical study in two oral presentations at the 54th Annual Meeting of the European Society for Paediatric Endocrinology on October 3, 2015, in Barcelona, Spain. The presentations included pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO’s hGH-CTP in comparison to a daily Genotropin® arm.

Help employers find you! Check out all the jobs and post your resume.